Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we’ll discuss how the U.S. government is cracking down on Chinese biotechs, and how that might affect the industry stateside. Also, a positive clinical trial for Ironwood Pharmaceuticals still causes a stock slump, and more.
Scrutiny of Chinese biotechs on the rise
The federal government and lawmakers have both been ramping up scrutiny of Chinese biotech companies lately. The Biden administration just issued an executive order directing federal health officials to guard against providing contracts and grants to companies, including U.S. firms, that could lead to foreign adversaries getting Americans’ sensitive health data.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect